Galenica AG

LSE:0ROG Stock Report

Market Cap: CHF 3.7b

Galenica Valuation

Is 0ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0ROG (CHF73.4) is trading below our estimate of fair value (CHF159.91)

Significantly Below Fair Value: 0ROG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ROG?

Key metric: As 0ROG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0ROG. This is calculated by dividing 0ROG's market cap by their current earnings.
What is 0ROG's PE Ratio?
PE Ratio21.6x
EarningsCHF 169.68m
Market CapCHF 3.67b

Price to Earnings Ratio vs Peers

How does 0ROG's PE Ratio compare to its peers?

The above table shows the PE ratio for 0ROG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.6x
MDC Mediclinic International
21.9x10.7%UK£3.7b
CTEC ConvaTec Group
37x20.2%UK£4.5b
SPI Spire Healthcare Group
32.2x26.9%UK£912.6m
SN. Smith & Nephew
35.3x22.7%UK£8.6b
0ROG Galenica
21.6x5.3%CHF 3.7b

Price-To-Earnings vs Peers: 0ROG is good value based on its Price-To-Earnings Ratio (21.6x) compared to the peer average (34.8x).

Price to Earnings Ratio vs Industry

How does 0ROG's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0ROG 21.6xIndustry Avg. 18.2xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0ROG is expensive based on its Price-To-Earnings Ratio (21.6x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ROG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.6x
Fair PE Ratio24.7x

Price-To-Earnings vs Fair Ratio: 0ROG is good value based on its Price-To-Earnings Ratio (21.6x) compared to the estimated Fair Price-To-Earnings Ratio (24.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ROG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 73.40
CHF 76.88
+4.7%
9.0%CHF 86.00CHF 68.00n/a4
Dec ’25CHF 76.65
CHF 76.88
+0.3%
9.0%CHF 86.00CHF 68.00n/a4
Nov ’25CHF 75.85
CHF 76.88
+1.4%
9.0%CHF 86.00CHF 68.00n/a4
Oct ’25CHF 74.52
CHF 76.38
+2.5%
8.2%CHF 84.00CHF 68.00n/a4
Sep ’25CHF 73.65
CHF 76.88
+4.4%
7.3%CHF 84.00CHF 70.00n/a4
Aug ’25CHF 76.45
CHF 77.00
+0.7%
7.4%CHF 84.00CHF 70.00n/a4
Jul ’25CHF 73.60
CHF 77.00
+4.6%
7.4%CHF 84.00CHF 70.00n/a4
Jun ’25CHF 74.70
CHF 77.00
+3.1%
7.4%CHF 84.00CHF 70.00n/a4
May ’25CHF 70.30
CHF 76.25
+8.5%
6.4%CHF 81.00CHF 70.00n/a4
Apr ’25CHF 75.21
CHF 76.25
+1.4%
6.4%CHF 81.00CHF 70.00n/a4
Mar ’25CHF 75.60
CHF 76.25
+0.9%
6.4%CHF 81.00CHF 70.00n/a4
Feb ’25CHF 75.79
CHF 76.25
+0.6%
6.4%CHF 81.00CHF 70.00n/a4
Jan ’25CHF 72.61
CHF 75.25
+3.6%
5.5%CHF 81.00CHF 70.00n/a4
Dec ’24CHF 72.44
CHF 75.00
+3.5%
5.1%CHF 80.00CHF 70.00CHF 76.654
Nov ’24CHF 68.21
CHF 74.50
+9.2%
4.3%CHF 78.00CHF 70.00CHF 75.854
Oct ’24CHF 67.91
CHF 73.50
+8.2%
5.0%CHF 78.00CHF 68.00CHF 74.524
Sep ’24CHF 69.72
CHF 73.40
+5.3%
4.4%CHF 78.00CHF 68.00CHF 73.655
Aug ’24CHF 70.09
CHF 72.40
+3.3%
4.2%CHF 76.00CHF 68.00CHF 76.455
Jul ’24CHF 72.54
CHF 72.40
-0.2%
4.2%CHF 76.00CHF 68.00CHF 73.605
Jun ’24CHF 71.11
CHF 73.75
+3.7%
3.5%CHF 77.00CHF 70.00CHF 74.704
May ’24CHF 79.94
CHF 70.50
-11.8%
9.3%CHF 77.00CHF 60.00CHF 70.304
Apr ’24CHF 77.36
CHF 69.50
-10.2%
8.3%CHF 75.00CHF 60.00CHF 75.214
Mar ’24CHF 72.41
CHF 68.75
-5.1%
7.5%CHF 73.00CHF 60.00CHF 75.604
Feb ’24CHF 71.49
CHF 68.75
-3.8%
7.5%CHF 73.00CHF 60.00CHF 75.794
Jan ’24CHF 76.02
CHF 68.75
-9.6%
7.5%CHF 73.00CHF 60.00CHF 72.614
Dec ’23CHF 71.33
CHF 68.50
-4.0%
7.3%CHF 72.00CHF 60.00CHF 72.444

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 13:31
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Galenica AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruno BulicBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Alexander BerglundBofA Global Research